Radiopharm Theranostics Progresses 177Lu-RAD202 Dose Escalation in HER2-Positive Tumors
Radiopharm Theranostics has received a positive recommendation to escalate the dose of its 177Lu-RAD202 radiotherapeutic in a Phase 1 trial targeting HER2-positive advanced solid tumors, maintaining its timeline to complete dose escalation by year-end 2026.
- Positive Data Safety and Monitoring Committee recommendation for dose escalation to 130mCi
- Phase 1 ‘HEAT’ trial progressing rapidly with favorable safety profile
- 177Lu-RAD202 targets HER2-positive advanced solid tumors including breast cancer
- Dose escalation expected to complete by end of 2026
- Trial conducted across multiple Australian clinical centres
Phase 1 Trial Progresses to Higher Dose Level
Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX) announced on 8 April 2026 that its Phase 1 clinical trial of 177Lu-RAD202 has advanced to the next dose level of 130mCi. This progression follows a positive recommendation from the Data Safety and Monitoring Committee (DSMC), which reviewed safety data and endorsed continuation of dose escalation in patients with HER2-positive advanced solid tumors.
The DSMC, a multidisciplinary panel responsible for monitoring patient safety and trial integrity, supported moving from Cohort 2 to Cohort 3 based on the favorable safety profile observed so far. The trial, known as ‘HEAT’, is being conducted at clinical centres across Australia and focuses on patients with tumors overexpressing the Human Epidermal Growth Factor Receptor 2 (HER2), a validated target in oncology notably in breast cancer.
About 177Lu-RAD202 and Trial Context
177Lu-RAD202 is a proprietary single-domain monoclonal antibody radiolabelled with lutetium-177, designed to selectively target HER2-positive tumors. Prior diagnostic studies involving ten breast cancer patients demonstrated clinical proof-of-concept with positive safety and biodistribution results. The current Phase 1 trial aims to establish safety and tolerability across escalating dose levels, with the previous dose level of 75mCi announced in October 2025.
CEO Riccardo Canevari highlighted the rapid trial progress and the company’s confidence in completing dose escalation by the end of 2026. This timeline aligns with Radiopharm’s broader clinical development strategy, which includes multiple trials across various solid tumor indications.
Broader Clinical Pipeline and Industry Position
Radiopharm Theranostics maintains a diversified oncology pipeline with several clinical-stage assets. Notably, the company recently secured a supply partnership with Siemens Healthineers for its RAD101 product, advancing a Phase 3 brain metastases trial in the United States. This program has shown promising interim data with 90% concordance to MRI imaging, underscoring Radiopharm’s expanding footprint in radiopharmaceutical oncology diagnostics and therapeutics.
The company’s pipeline also includes Phase 1 trials targeting prostate cancer and other solid tumors, reflecting a strategic focus on radiolabelled antibodies and peptides. Investors and observers will likely monitor upcoming clinical data releases and regulatory updates to assess the evolving risk and opportunity profile of Radiopharm’s portfolio.
Bottom Line?
Radiopharm’s dose escalation in the 177Lu-RAD202 Phase 1 trial marks steady clinical progress, though efficacy and broader trial outcomes remain to be seen.
Questions in the middle?
- How will the safety and efficacy data from the 130mCi dose cohort influence subsequent trial phases?
- What are the anticipated timelines and milestones beyond dose escalation for 177Lu-RAD202?
- How might Radiopharm’s expanding clinical pipeline, including RAD101 and RAD402, impact its competitive positioning in oncology radiopharmaceuticals?
